Domenico Ribatti
University of Bari
965 Papers
6.1K Citations
Domenico Ribatti is an academic researcher from University of Bari. The author has contributed to research in topics: Angiogenesis & Biology. The author has an hindex of 96, co-authored 913 publications. Previous affiliations of Domenico Ribatti include University of Genoa & National Institutes of Health.
Chat about Author
Papers
Enhanced anti-tumor and anti-angiogenic efficacy of a novel liposomal fenretinide on human neuroblastoma
Daniela Di Paolo,Fabio Pastorino,Guendalina Zuccari,Irene Caffa,Monica Loi,Danilo Marimpietri,Chiara Brignole,Patrizia Perri,Michele Cilli,Beatrice Nico,Domenico Ribatti,Vito Pistoia,Mirco Ponzoni,Gabriella Pagnan +13 more
TL;DR: A novel HPR formulation, by which the drug was encapsulated into sterically stabilized nanoliposomes according to the Reverse Phase Evaporation method, could be considered as an adjuvant tool in the future treatment of neuroblastoma patients.
Combined Replenishment of miR-34a and let-7b by Targeted Nanoparticles Inhibits Tumor Growth in Neuroblastoma Preclinical Models.
Daniela Di Paolo,Fabio Pastorino,Chiara Brignole,Maria Valeria Corrias,Laura Emionite,Michele Cilli,Roberto Tamma,Leslie Priddy,Adriana Amaro,Davide Ferrari,Roberto Marotta,Elisa Ferretti,Ulrich Pfeffer,Domenico Ribatti,Angela Rita Sementa,David Brown,Naohiko Ikegaki,Hiroyuki Shimada,Mirco Ponzoni,Patrizia Perri +19 more
TL;DR: In this paper, NB-targeted nanoparticles, individually and more powerfully in combination, significantly reduce cell division, proliferation, neoangiogenesis, tumor growth and burden, and induces apoptosis in orthotopic xenografts and improves mice survival in pseudometastatic models.
Angiogenesis in Pancreatic Cancer: Pre-Clinical and Clinical Studies.
TL;DR: The purpose is to identify new anti-angiogenic molecules that may enhance treatment regimen and to discuss the anti-Angiogenic therapy paradox between the advantage to abolish vessel supply to block tumor growth and the disadvantage due to reduction of drug delivery at the same time.
Evolution toward beta common chain receptor usage links the matrix proteins of HIV-1 and its ancestors to human erythropoietin.
Francesca Caccuri,Pasqualina D'Ursi,Matteo Uggeri,Matteo Uggeri,Antonella Bugatti,Pietro Mazzuca,Alberto Zani,Federica Filippini,Mario Salmona,Domenico Ribatti,Mark Slevin,Alessandro Orro,Wuyuan Lu,Pietro Liò,Robert C. Gallo,Arnaldo Caruso +15 more
TL;DR: In this paper, a functional epitope that displays molecular mimicry with human erythropoietin (EPO) and promotes angiogenesis through common beta chain receptor (βCR) activation was identified.
Tumor Regression and Curability of Preclinical Neuroblastoma Models by PEGylated SN38 (EZN-2208), a Novel Topoisomerase I Inhibitor
Fabio Pastorino,Monica Loi,Puja Sapra,Pamela Becherini,Michele Cilli,Laura Emionite,Domenico Ribatti,Lee M. Greenberger,Ivan D. Horak,Mirco Ponzoni +9 more
TL;DR: EZN-2208 should be considered a most promising novel antineuroblastoma agent and an ongoing phase I study in pediatric patients should identify the optimal dose for a phase II study.